Xiaofan was awarded her Ph.D. in Organic Chemistry at Northeastern University, MA in August 2019. Xiaofan studied under the direction of Dr. George O’Doherty and worked on asymmetric synthesis, total synthesis and medicinal chemistry. She also has experience as a process development chemist gained at Biogen in Cambridge, MA. Xiaofan joined the LDDN in September 2019.
Matteo received a BSc in Chemistry from the College of the Holy Cross, MA in 2019. Matteo is a Research Assistant and joined the LDDN in May 2019.
Luu received a BSc in Chemistry at Northeastern University, MA in May 2020. During his degree, he gained research experience as a medicinal chemist during a six month coop placement at both the LDDN and in organic synthesis at Merck Research Laboratories in Boston, MA. Luu Pham re-joined the LDDN in July 2020.
Dawid Fiejtek originally joined the group back in January of 2017, as a coop student from Northeastern University. Dawid worked on the synthesis of new analogs in our SMA series that increases transcription of the survival motor neuron protein for the treatment of Spinal Muscular Atrophy. Dawid was then a research scientist at the LDDN working on SMA and other CNS projects. In the future, Dawid plans to attend medical school.
Mike Shultis was a recent chemistry graduate from Northeastern University and joined the group back in April 2018, as a research scientist. Mike was working on the synthesis of novel molecules for the EAAT2 project. In the future, Mike plans to pursue a career as a physician-researcher.
Greg Ahn Had graduated from Cornell University and joined the group back in September 2017, as a research scientist. Greg was working on the synthesis of novel molecules as potential treatments for renal carcinoma. Greg had started medical school in 2019.
Dr. Xuechao Xing was a Senior Research Scientist and Instructor at the LDDN. Having joined the LDDN in 2001, Xuechao made major contributions to multiple LDDN projects including necrosis inhibitors, BMP, SMA, and EAAT2. Xuechao is currently working as a medicinal chemist at Enanta Pharmaceuticals in Watertown, MA.
Dr. Xiao (Elliot) Wang was a Researcher and Instructor at the LDDN.
Dr. Wang originally joined the LDDN as a postdoctoral Research Fellow in Medicinal Chemistry in 2011, and was promoted to Instructor in 2012. His research efforts were aimed at optimizing small molecules for the Klotho and EAAT2 projects as potential treatments for neurodegeneration. In 2017 Elliot returned to China to continue his research career.
Dr. Hrvoje (Harry) Lusic joined the LDDN as a postdoctoral research fellow in medicinal chemistry in 2013.
Harry made many key contributions to multiple projects including for SMA, CMT, ALS and Alzheimer’s disease. Harry left the LDDN in 2017 and is teaching at North Carolina A&T University in Greensboro.
Alyssa Calder originally joined the LDDN in January 2014 as a Northeastern coop student and after graduation from Northeastern in 2015 she rejoined the LDDN as a Research Associate. Alyssa made many important contributions to the SMA project. In 2017 she left the LDDN to begin her medical career at Drexel University College of Medicine.
Katherine Taylor had joined the group back in August of 2018. She was an undergraduate chemistry student from Bath University UK.
Samuel Bowler had joined the group back in July of 2018. Sam was a final year Masters chemistry student from Lincoln University UK. Sam was working on the synthesis of new molecules to treat neurodegenerative diseases.
Aaron Chambers had joined the group back in July of 2018. Aaron was a final year Masters chemistry student from Lincoln University UK. Aaron was working on the synthesis of new molecules to treat neurodegenerative diseases.
Lin Lin originally joined the group in January 2015, as a coop student from Northeastern University. Lin developed the SAR on the SOD1 and CMT projects. After graduating from Northeastern, Lin is now back at the LDDN and making key contributions to the EAAT2 and HIF projects. In the future, Lin plans to attend medical school.
Lisa Montagnon joined the group in September 2017. She is an undergraduate chemistry student from Bath University UK. Lisa is synthesizing new heterocycles for the EAAT2 project for the treatment of AD and ALS.
Hamilton Coulter joined the group in September 2017 and is an chemist from Bath University UK. Hamilton is working on the synthesis of different heterocycles that modulate the activity of the innate immune system in the CNS for the treatment of neurodegenerative diseases.
Kristy Ngai was a student from the University of Bath, UK, studying for a BSc (Hons) in Natural Sciences (Major in Pharmacology, Minor in Organic Chemistry). Kristy made new anlogs of lead HIF2a inhibitor as a potential treatment for renal cancer.
Anna Blundell was a student from the University of Bath studying for an MSci (Hons) in Natural Sciences (Major in Chemistry, Minor in Pharmacology. Anna spent her third year placement here at the LDDN. She developed new SAR for the EAAT2 project for the treatment of AD and ALS.
Eva Rodger studied Medicinal Chemistry with Professional Studies BSc (Hons) at the University of Salford. Eva worked on the synthesis and SAR of substituted benzothiazoles for the treatment of neurodegenerative diseases including MS and SMA.
Xiao Liu was a MChem student from the University of York, U.K. and joined the group in September 2016. Xiao worked on the synthesis of Etifoxine and its analogs. Xiao is pursuing a PhD at the University of Oxford.
Patrick Boaler was a MChem student from the University of York, U.K. and joined the group in August 2016. Patrick focused his research on the synthesis of more water soluble analogs of one of our lead SMA series. Patrick is pursuing a PhD at the University of Edinburgh in Scotland.
Ian Hope was a final year MChem student from the University of York, U.K. Ian joined the group in August 2016 and developed SAR for compounds that increase protein expression of EAAT2 protein as potential treatments for AD and ALS
Matthew Okscin (Fall 2014). In his six months at the LDDN, Matthew made novel analogs for a number of projects. Notably, he identified a compound that significantly suppressed SOD1 expression. Matthew is now on his second coop, also at BWH as an infant hearing screening technician. Matthew plans to go to medical school following graduation from Northeastern.
Alyssa Calder (Spring 2014). Alyssa spent her six months at the LDDN working on the SMA project. She was able to synthesize all of the crazy heterocycles I asked her to make, and she added a few more on top. She helped put the SMA project where it is today. Alyssa rejoined the LDDN in the fall of 2014, for her final year research project and made probe compounds to help elucidate the molecular target of our molecules. Alyssa began medical school at Drexel University College of Medicine.
Alexis Balcom (Fall 2013). Alexis began the novel CNS library project and made a number of new templates. One of Alexis’s compounds was found to significantly increase expression of the SMN-2 protein, and it became the new lead structure for the SMA project. Alexis is now back at Northeastern, heading into her final semester.
Jennifer Li (Spring 2013). Jennifer became our process chemist during her six month stay. She was focused on scaling-up 10-10, the lead compound for the EAAT2 project at that time.
Rutali Brahme (Spring 2014). Rutali determined the thermodynamic and kinetic solubility, and the microsomal stability of a number of important LDDN compounds. Rutali began development of a PAMPA permeability assay before she joined Novartis in Cambridge, MA.
Sinthia Ahmed (Fall 2013). Sinthia determined the thermodynamic and kinetic solubility, and the microsomal stability of a number of important LDDN compounds. Sinthia also began to profile the hits discovered from screening the LDDN library in these assays which has helped us to design new libraries for CNS indications with better physical properties. Sinthia is now a formulation chemist at Toxikon in Bedford, MA.
Manpreet Virk (Spring 2013). Manpreet and Fera pioneered our development of in house microsomal stability, solubility and logD assays. Through their contributions, we were able to rapidly profile compounds in important drug-like property assays and prioritize compounds for in vivo studies. Manpreet is currently an Associate Scientist working at Cyprotex in Watertown, MA.
Fera Soedarsono (Spring 2013). Fera and Manpreet pioneered our development of in house microsomal stability, solubility and logD assays. Through their contributions, we were able to rapidly profile compounds in important drug-like property assays and prioritize compounds for in vivo studies. I am indebted to Fera, as she has always been available to come back to the LDDN to train new students and to help with the assays. Fera is a Scientist working at Novartis in Cambridge, MA.